A randomised clinical trial comparing endovenous laser ablation and mechanochemical ablation (ClariVein®) in the management of superficial venous insufficiency.
Varicose veins, a very common problem in UK, may cause symptoms including pain, heaviness and itching in the lower legs. Overtime, bleeding and damage to surround soft tissues may develop, leading to venous ulcer which can be very painful, debilitating, difficult to heal and very expensive to treat. Newer minimally invasive techniques are preformed using local anaesthetic. The recovery has been shown to be more rapid, due to less pain and disability when compared to open surgery. These techniques use either heat or a chemical/medicine injected inside the varicose veins to close them permanently. In 2013 National Institute of Health and Care Excellence (NICE) recommended that methods using heat such as endovenous laser ablation (EVLA) should be first choice as the chemical methods have been shown to have a significantly lower treatment success rates in closing varicose veins permanently. Chemical methods however do have their advantages, as they require far fewer injections of local anaesthetic than the heat methods and these injections can be a source of significant discomfort. Since NICE guidelines, a new treatment technique known as mechanochemical ablation (MOCA) using ClariVein® has been developed. This device injects a chemical into the vein through a rotating hollow wire, which causes the vein to narrow and damages the lining of the vein, making the chemical more effective. This new treatment technique aims to match the success rates of the heat method, but with less pain since it avoids most of the local anaesthetic injections. Both treatments are currently used in the UK, however there is insufficient evidence as to whether one is better, or the same. This trial will randomly allocate volunteer patients to have their varicose veins treated with either EVLA or MOCA. The investigators will assess a range of outcomes including pain scores, success rates, complications, quality-of-life and costs to see which, if any, of these treatments offer better results. Long term follow-ups will occur at 5 and 10 years.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
150
1% Lidocaine with 1:200,000 epinephrine will be used for skin infiltration. The EVLA fibre is introduced into the vein using the Seldinger technique and its tip will be positioned under duplex ultrasound (DUS). Then tumescent anaesthetic, made of a solution of 100ml of 1% Lidocaine with 1:200,000 epinephrine in 900ml of 0.9% Sodium Chloride and buffered to pH 7.4 with 10ml of 8.4% Sodium Bicarbonate, will be infiltrated around the target axial vein under DUS using a spinal needle and a peristaltic pump. Following deployment of appropriate laser safety precautions, the laser energy will be delivered via the fibre. The wavelength used is 1470nm, with NeverTouch Gold-Tip fibre, at 10W power. This laser light energy is converted into heat inducing a permanent, non-thrombotic occlusion.
1% Lidocaine with 1:200,000 epinephrine will be used for skin infiltration. MOCA is performed by a device called ClariVein® (Vascular Insights, UK) which is a long thin catheter that is passed up inside the vein, with a rotating wire that protrudes at an angle from the end when deployed. This is motorised via an electric motor in the handle and rotates at approximately 3500 revolutions per minute. In addition, liquid sclerotherapy is injected at the handle end by a syringe. This sclerotherapy liquid emerges from the end of the catheter and is present in the area of the rotating tip. The sclerosant will be Sodium Tetradecyl Sulphate (STS), marketed as Fibrovein. Concentration of 1.5% Fibrovein will be used, and maximum of 12ml.
Hull and East Yorkshire Hospitals NHS Trust
Hull, United Kingdom
Intra-procedural Pain
Patient is asked immediately after the procedure of their level of pain experienced during the intervention; measured on a standardised visual analogue scale (VAS).
Time frame: Up to end of intervention
Technical Efficacy assessed by successful procedure defined as complete occlusion of the target vein segment.
Time frame: At 1 year
Aberdeen Varicose Vein Questionnaire (AVVQ)
Disease Specific quality of life
Time frame: 1 week, 6 weeks, 6 months, 1 year
Chronic Venous disease quality of life Questionnaire (CIVIQ-20)
Disease Specific quality of life
Time frame: 1 week, 6 weeks, 6 months, 1 year
VEnous INsufficiency Epidemiological and Economic Study to evaluate Quality of Life and Symptoms (VEINES-QOL/Sym)
Disease Specific quality of life
Time frame: 1 week, 6 weeks, 6 months, 1 year
Short Form 36
Generic quality of life
Time frame: 1 week, 6 weeks, 6 months, 1 year
EuroQol (EQ5D)
Generic quality of life
Time frame: 1 week, 6 weeks, 6 months, 1 year
Post-procedural Pain
One week pain diary
Time frame: Throughout the first week after the procedure
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
It is used as local anaesthetic given via subcutaneous injection, so that the skin is numb prior to the introduction of either endovenous laser ablation or mechenochemical ablation catheter. Typically 1-2ml is required.
100ml of 1% lidocaine with 1:200,000 epinephrine is diluted into 900ml of 0.9% Sodium Chloride to make the tumescent anaesthetic solution, which is required when using endovenous laser ablation.
10ml of 8.4% Sodium Bicarbonate is added into the tumescent anaesthetic solution, to buffer the pH to 7.4. Tumescent anaesthetic solution is required when using endovenous laser ablation.
1.5% of Sodium Tetradecyl Sulphate, marketed as Fibrovein, will be used with the mechanochemical ablation device (ClariVein®). This is a sclerosing agent with Manufacturer Authorisation, and it will be used unmodified. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein.
Analgesia Use
One week analgesia diary
Time frame: 1 week
Bruising visual analogue scale
Appreciation of the severity of bruising
Time frame: 1 week, 6 weeks, 6 months, 1 year
Satisfactory visual analogue scale
Satisfaction with treatment
Time frame: 1 week, 6 weeks, 6 months, 1 year
Cosmesis visual analogue scale
Satisfaction with cosmetic result from treatment
Time frame: 1 week, 6 weeks, 6 months, 1 year
Recovery time
Time taken to return to work (if employed) and daily activity
Time frame: 1 week, 6 weeks, 6 months, 1 year
Complications
Any numbness, persistent bruising, tenderness, skin loss/ulceration, lumpiness, development of thread, skin staining, wound infection, deep vein thrombosis, pulmonary embolus, stroke, loss of vision, damage to major artery, vein or nerve.
Time frame: 1 week, 6 weeks, 6 months, 1 year
Recurrence of Varicose Veins
Combination of history taking, clinical examination and duplex ultrasound assessment.
Time frame: 1 week, 6 weeks, 6 months, 1 year
Disease Progression
Comparison of clinical and duplex ultrasound findings between follow-ups.
Time frame: 1 week, 6 weeks, 6 months, 1 year
Need for Further Treatment
Comparison of clinical and duplex ultrasound findings between follow-ups is made and should there be failure of intervention or recurrence of varicose veins, there would be consultation between surgeon and patient to decide whether further intervention is required.
Time frame: 1 week, 6 weeks, 6 months, 1 year